Novo Nordisk Insiders Sit Out the Rally While the Company Keeps Writing Checks

Novo Nordisk's boardroom has gone quiet on the personal-investment front. Not a single sitting member of the Danish drugmaker's executive team has put their own money into the stock since June 2024, according to reporting by Danish outlets Finans and MedWatch. Contractually awarded remuneration and anniversary shares are the only additions to have landed in their portfolios over that stretch.

The silence is awkward for a company trying to talk up its own value. Per Hansen, investment economist at broker Nordnet, argues the absence of private purchases undercuts shareholder faith in a durable turnaround for the share price. Novo Nordisk declined to comment on the substance of the reports, pointing instead to the statutory quiet period ahead of its next interim statement.

The company is buying even if the executives aren't

On the corporate side, the checkbook stays open. Novo Nordisk picked up 1,225,000 of its own B shares in the past trading week, part of a repurchase programme launched in February with a ceiling of up to DKK 15 billion. By mid-October the group had bought back stock for roughly DKK 10.88 billion, leaving it holding about 1.2% of total share capital in treasury.

That steady stream of transactions is meant to tighten the supply of shares in the market and hand excess cash back to owners. Management frames it as a show of reliability at a moment when pricing debates and competitive pressure on GLP-1 therapies dominate the conversation.

A share price still hunting for a floor

Investors have yet to be convinced. The stock changed hands at EUR 34.25 at yesterday's close and sits roughly 37% below its 52-week high, with a year-to-date loss of 22%. Sentiment took another knock when BMO Capital trimmed its price target to $40, citing market-share losses for Ozempic in the US. HSBC has also cut its target on the Danish name.

Competition is closing in from several directions, with rival pharma companies pushing their own obesity and diabetes compounds in a bid to capture share.

India growth and a US pipeline waiting on the FDA

Beyond capital allocation, international expansion is moving up the agenda. Management expects the Indian market for GLP-1 therapies to grow 15% to 20% annually, according to media reports, and an oral obesity treatment could launch there around mid-2027, subject to regulatory approvals. The company is also expanding its own service centres to support operations.

In the US, the FDA is still reviewing the haemophilia A drug Denecimig after fixes were required at a manufacturing site. The agency raised no objections to the clinical safety and efficacy data. Novo Nordisk is targeting a US launch for Denecimig in the first half of 2027, and its full-year financial outlook remains unchanged.

Guidance points to a flat-to-lower year

The numbers behind the caution are plain. At constant currencies, Novo Nordisk expects revenue at best to stall and at worst to fall by up to 6%. Adjusted operating profit carries the same range: flat to down 6%.

All eyes now turn to 4 November, when the company reports results for the first three quarters and gives the market its freshest read on how the competitive landscape is biting.